---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-012870"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:56:07.564844+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio completes Phase I dose cohort for INKmune in mCRPC, opens Phase II

## Summary
- Third and highest dose cohort of Phase I completed; no safety issues found.
- Scientific Review Committee unanimously voted to open all Phase II cohorts of CaRePC trial.
- Low dose cohort showed immunologic effects; higher dose cohorts to assess therapeutic benefits.
- CEO R.J. Tesi noted INKmune given in outpatient setting with exemplary safety profile.
- CSO Mark Lowdell invited to speak at 10th Annual Innate Killer Summit on March 4.

## SEC filing metadata
- accession: 0001213900-25-012870
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/0001213900-25-012870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/ea0230833-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-012870
- JSON: https://secwatch.observer/filing/0001213900-25-012870.json
- Plain text: https://secwatch.observer/filing/0001213900-25-012870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.